Table IV.
Variables | ALL 111 (75.51) |
AML 36 (24.49) |
Healthy individuals 100 (100) |
P-valueb |
---|---|---|---|---|
Age (years, mean ± SD) | 7.73±4.91 | 8.02±4.79 | 10.21±5.53 | 0.002d |
No. of leukocytes/mm3 | 19,700 (4,700–42,900)a | 34,550 (9,350–68,000)a | 8,000 (7,000–9,000)a | <0.001d |
Gender | ||||
Female | 41 (36.94) | 14 (38.89) | 47 (47.00) | 0.317 |
Male | 70 (63.06) | 22 (61.11) | 53 (53.00) | |
Status of participants | ||||
Alive | 42 (37.84) | 13 (36.11) | 100 (100.00) | 1.00c |
Deceased | 69 (62.16) | 23 (63.89) | - | |
Risk by age and leukocytes at diagnosis | ||||
Low-risk (1–10 years and <50,000 leukocytes/mm3) | 48 (43.24) | 12 (33.33) | - | 1.00c |
High-risk (<1 and >10 years and >50,000 leukocytes/mm3) | 63 (56.76) | 24 (66.67) | - | |
Relapse during treatment | ||||
No | 40 (36.04) | 17 (47.22) | - | |
Yes | 71 (63.96) | 19 (52.77) | - | 0.244c |
Immunophenotype | ||||
B-lineage | 93 (83.78) | - | - | - |
T-lineage | 11 (9.91) | - | - | |
B/T-lineage | 7 (6.31) | - | - | |
FAB classification | ||||
L1 | 93 (83.78) | - | - | - |
L2 | 18 (16.22) | - | - | |
M0 | - | 10 (27.77) | - | |
M1 | - | 14 (38.89) | - | - |
M2 | - | 6 (16.67) | - | |
M3 | - | 6 (16.67) | - | |
Chromosomal translocations | ||||
ETV6-RUNX1 [t(12;21)] | 1 (0.90) | - | - | |
BCR-ABL [t(9;22)] | 7 (6.31) | - | - | |
AML1-ETO [t(8;21)] | - | 3 (8.33) | - | |
CBFB-MYH11 [inv(16)] | - | 0 (0.00) | - | - |
Negative | 64 (57.66) | 22 (61.11) | - | |
Not determined | 39 (35.13) | 11 (30.56) | - | |
miR-24 levels | 0.84 (0.21–2.54)a | 4.22 (2.08–8.22)a | 1.25 (1.09–1.61)a | <0.001d |
Data are expressed as n (%) unless indicated otherwise;
median (percentiles 25–75).
Obtained by the Chi-square test.
p-value obtained between patients with ALL and AML.
Significant p<0.05.
AL, acute leukemia; ALL, acute lymphoblastic leukemia AML, acute myeloid leukemia.